67 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
salaries and bonuses and grants equity incentive awards to our executive officers. In setting base salaries and bonus targets, our compensation
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
with Incyte Corporation, or Incyte, will yield any validated targets, whether Incyte will exercise any of its options to exclusively license … intellectual property directed to such targets, and whether and when any of the target validation fees, option exercise fees, milestone payments or royalties
8-K
rak6posa7y9wrw6m6t
11 Aug 23
Termination of a Material Definitive Agreement
4:30pm
424B5
nedf pml9
1 May 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
btfty48lvlf8i 2mh3
12 Dec 22
Regulation FD Disclosure
7:48am
425
vx560 ae75v
2 Sep 22
Business combination disclosure
4:03pm
8-K
2zqtzk0 4u
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
424B3
z4d0h4
8 Aug 22
Prospectus supplement
5:47pm
S-4
135v4 02r
18 Jul 22
Registration of securities issued in business combination transactions
7:58am